Page 3 - Markl Baum News Today

Second Quarter 2023 and Recent Selected Highlights: Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in...

VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)...

Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUSNASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of a...

Harrow has signed agreements with affiliates of Santen Pharmaceutical to acquire certain US and Canadian commercial rights.

18.07.2023 - Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Novaliq GmbH, a German biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced an agreement under which Harrow will acquire the ... Seite 1

18.07.2023 - Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights ... Seite 1

HROW | Complete Harrow Health Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Operator: Good afternoon, and welcome to Harrows First Quarter 2023 Earnings Conference Call. My name is Joe, and I will be your operator for todays call.

The pharmaceutical company announced first-quarter earnings Thursday afternoon.

Harrow, a leading U.S. eyecare pharmaceutical company, entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management. The interest-only secured credit facility carries an interest rate equal to the three-month secured overnight financing rate (SOFR) plus 6.50%, includes flexible terms and covenants...